Sign In
Buy BLCM
$0.0748
+0 (+0%)
At Close: Jun 03, 2024
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
01:00pm, Thursday, 16'th Mar 2023
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
04:30pm, Tuesday, 14'th Mar 2023
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and p
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
11:17am, Monday, 27'th Feb 2023
Here is how Bellicum Pharmaceuticals (BLCM) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:43pm, Tuesday, 31'st Jan 2023
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 4
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:36pm, Tuesday, 31'st Jan 2023
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducem
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
07:30am, Thursday, 19'th Jan 2023
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstr
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
10:00am, Sunday, 11'th Dec 2022
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster pres
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:49pm, Monday, 31'st Oct 2022 GlobeNewswire Inc.
HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity induc
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
11:30am, Tuesday, 04'th Oct 2022 GlobeNewswire Inc.
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick F
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
07:30am, Tuesday, 04'th Oct 2022
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fai
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity ind
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
11:30am, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
07:30am, Thursday, 01'st Sep 2022
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fa
Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now
01:55pm, Thursday, 25'th Aug 2022 Zacks Investment Research
After losing some value lately, a hammer chart pattern has been formed for Bellicum Pharmaceuticals (BLCM), indicating that the stock has found support. This, combined with an upward trend in earnings
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
01:40pm, Thursday, 18'th Aug 2022 Zacks Investment Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Bellicum Pharmaceuticals (BLCM) have performed compared to their sector so far this year.
